{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:25:51Z","timestamp":1786404351994,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1182950"],"award-info":[{"award-number":["1182950"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cambodia has targeted malaria elimination by 2025. As the malaria burden has decreased in Cambodia, transmission has become more focal, and\n                    <jats:italic>Plasmodium vivax<\/jats:italic>\n                    has become the predominant species. The recurrent nature of\n                    <jats:italic>P. vivax<\/jats:italic>\n                    , due to its dormant liver stages causing relapses, is the main obstacle to malaria elimination in Cambodia. In 2021, Cambodia\u2019s National Center for Parasitology, Entomology and Malaria Control (CNM) rolled out low-dose 14-day primaquine (total dose 3.5\u00a0mg\/kg) supported by point-of-care quantitative testing for glucose-6-phosphate dehydrogenase deficiency. However, this treatment is limited by poor adherence to its prolonged duration and suboptimal efficacy of the low total dose. The EFFORT clinical trial was conducted in four malaria-endemic countries, including Cambodia, to assess the safety and effectiveness of a 7-day unsupervised high-dose course of primaquine (7\u00a0mg\/kg total dose) and single dose tafenoquine (300\u00a0mg) compared to 14-day unsupervised low-dose primaquine for the treatment of patients presenting with\n                    <jats:italic>P. vivax<\/jats:italic>\n                    malaria. In addition, data were collected on the feasibility and cost-effectiveness of these treatment options. CNM organized the national dissemination of the EFFORT study results on March 27, 2025, to inform key stakeholders and discuss the implications of the study findings for policy and practice in Cambodia.\n                  <\/jats:p>","DOI":"10.1186\/s12936-025-05691-1","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:31:17Z","timestamp":1767432677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Moving towards high-dose primaquine or single-dose tafenoquine for Plasmodium vivax treatment in Cambodia: a meeting report from dissemination of results of the EFFORT trial to stakeholders"],"prefix":"10.1186","volume":"25","author":[{"given":"Lek","family":"Dysoley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cassidy-Seyoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaryan","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nead","family":"Phoumen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin","family":"Srey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Touch","family":"Phalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prak","family":"Vonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"But","family":"Engrkruy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oum","family":"Sovanarath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hor","family":"Mengkea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pov","family":"Rathana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv","family":"Makara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pen Kim","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yim","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huot","family":"Khlok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khourn","family":"Pong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tov","family":"Moeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Vantha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ung","family":"Soviet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Ravuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voeurng","family":"Bunreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keo","family":"Vannak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma","family":"Sokhann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Kimmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khoy","family":"Dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siv","family":"Samol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koung","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuon","family":"Sokunthea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hok","family":"Kry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly","family":"Kanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leng","family":"Naren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarith","family":"Oum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok","family":"Sovann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros","family":"Channavuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chhun","family":"Bunmeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayme","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Brindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sovann","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prum","family":"Mardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Im","family":"Chanry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sodavuth","family":"Preap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socheat","family":"Heoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farooq","family":"Sabawoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoang","family":"Sokha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Ringwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupam","family":"Tripura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"von Seidlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamala","family":"Thriemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"5691_CR1","doi-asserted-by":"crossref","unstructured":"Cui L, Cao Y, Kaewkungwal J, Khamsiriwatchara A, Lawpoolsri S, Soe TN, et al. Malaria Elimination in the Greater Mekong Subregion: Challenges and Prospects. In: Manguin S, Dev V (eds.). Towards Malaria Elimination - A Leap Forward [Internet]. InTechOpen; 2018 [cited 2021 Sept 30]. Available from: http:\/\/www.intechopen.com\/books\/towards-malaria-elimination-a-leap-forward\/malaria-elimination-in-the-greater-mekong-subregion-challenges-and-prospects","DOI":"10.5772\/intechopen.76337"},{"key":"5691_CR2","unstructured":"Kingdom of Cambodia Ministry of Health. Cambodia National Malaria Elimination Framework 2016 - 2020. Phnom Penh, Cambodia; 2016."},{"key":"5691_CR3","unstructured":"WHO. Strategy for malaria elimination in the Greater Mekong Subregion\u202f: 2015\u20132030 [Internet]. Manila: Regional Office for the Western Pacific; World Health Organization; 2015 [cited 2021 Dec 13]. Available from: http:\/\/iris.wpro.who.int\/handle\/10665.1\/10945"},{"key":"5691_CR4","unstructured":"Kingdom of Cambodia Ministry of Health. Cambodia Malaria Elimination Action Framework 2021\u20132025 [Internet]. Phnom Penh, Cambodia; 2020. Available from: https:\/\/www.cnm.gov.kh\/index.php?action=ID6"},{"key":"5691_CR5","volume-title":"Mekong malaria elimination\u202f: epidemiology summary, volume 13, January-March, 2021","author":"WHO","year":"2021","unstructured":"WHO. Mekong malaria elimination\u202f: epidemiology summary, volume 13, January-March, 2021. Geneva: World Health Organization; 2021."},{"key":"5691_CR6","unstructured":"WHO. Mekong Malaria Elimination: epidemiology summary, volume 20, October - December 2022 [Internet]. Geneva, World Health Organization; 2023. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/366565\/WHO-UCN-GMP-MME-2023.01-eng.pdf?sequence=1"},{"key":"5691_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-6-37","volume":"6","author":"S Incardona","year":"2007","unstructured":"Incardona S, Vong S, Chiv L, Lim P, Nhem S, Sem R, et al. Large-scale malaria survey in Cambodia: novel insights on species distribution and risk factors. Malar J. 2007;6:37.","journal-title":"Malar J"},{"key":"5691_CR8","unstructured":"WHO. Mekong malaria elimination: epidemiology summary, volume 24, October\u2013December 2023 [Internet]. Geneva, World Health Organization; 2024 [cited 204 AD July 26]. Available from: https:\/\/www.who.int\/publications\/i\/item\/B09068"},{"key":"5691_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1475-2875-10-297","volume":"10","author":"NJ White","year":"2011","unstructured":"White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297.","journal-title":"Malar J"},{"key":"5691_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1475-2875-13-144","volume":"13","author":"KE Battle","year":"2014","unstructured":"Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144.","journal-title":"Malar J"},{"key":"5691_CR11","unstructured":"World Health Organization. Control and elimination of Plasmodium vivax malaria: a technical brief. Geneva, World Health Organization [Internet]. 2015; Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/181162\/9789241509244_eng.pdf"},{"key":"5691_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028357","volume":"6","author":"S Kim","year":"2011","unstructured":"Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of the CareStart\u2122 G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS ONE. 2011;6:e28357.","journal-title":"PLoS ONE"},{"key":"5691_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116143","volume":"9","author":"A Roca-Feltrer","year":"2014","unstructured":"Roca-Feltrer A, Khim N, Kim S, Chy S, Canier L, Kerleguer A, et al. Field trial evaluation of the performances of point-of-care tests for screening G6PD deficiency in Cambodia. PLoS ONE. 2014;9:e116143.","journal-title":"PLoS ONE"},{"key":"5691_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10038-005-0279-z","volume":"50","author":"H Matsuoka","year":"2005","unstructured":"Matsuoka H, Nguon C, Kanbe T, Jalloh A, Sato H, Yoshida S, et al. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Cambodia: G6PD Viangchan (871G>A) is the most common variant in the Cambodian population. J Hum Genet. 2005;50:468\u201372.","journal-title":"J Hum Genet"},{"key":"5691_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12936-019-2652-y","volume":"18","author":"G Bancone","year":"2019","unstructured":"Bancone G, Menard D, Khim N, Kim S, Canier L, Nguong C, et al. Molecular characterization and mapping of glucose-6-phosphate dehydrogenase (G6PD) mutations in the Greater Mekong Subregion. Malar J. 2019;18:20.","journal-title":"Malar J"},{"key":"5691_CR16","unstructured":"WHO. Guidelines for the treatment of malaria [Internet]. 3rd ed. Geneva: World Health Organization; 2015 [cited 2021 Dec 13]. 313 p. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/162441"},{"key":"5691_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12050650","volume":"12","author":"A Sadhewa","year":"2023","unstructured":"Sadhewa A, Cassidy-seyoum s, acharya s, devine a, price rn, mwaura m, et al. A review of the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria. Pathogens. 2023;12:650.","journal-title":"Pathogens"},{"key":"5691_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003476","volume":"4","author":"SA Cassidy-Seyoum","year":"2024","unstructured":"Cassidy-Seyoum SA, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, von Seidlein L, et al. Implementation of glucose-6-phosphate dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia. PLoS Glob Public Health. 2024;4:e0003476.","journal-title":"PLoS Glob Public Health"},{"key":"5691_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12936-024-04884-4","volume":"23","author":"D Lek","year":"2024","unstructured":"Lek D, Tsai YC, Hirano J, Sovannaroth S, Bunreth V, Vonn P, et al. Radical cure for Plasmodium vivax malaria after G6PD qualitative testing in four provinces in Cambodia, results from Phase I implementation. Malar J. 2024;23:56.","journal-title":"Malar J"},{"key":"5691_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12936-017-1784-1","volume":"16","author":"K Thriemer","year":"2017","unstructured":"Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malar J. 2017;16:141.","journal-title":"Malar J"},{"key":"5691_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12936-018-2380-8","volume":"17","author":"K Thriemer","year":"2018","unstructured":"Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J. 2018;17:241.","journal-title":"Malar J"},{"key":"5691_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-023-04725-w","volume":"22","author":"P Mehdipour","year":"2023","unstructured":"Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, et al. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. Malar J. 2023;22:306.","journal-title":"Malar J"},{"key":"5691_CR23","volume-title":"National treatment guidelines for malaria in Cambodia","author":"National Center for Parasitology, Entomology and Malaria Control (CNM)","year":"2022","unstructured":"National Center for Parasitology, Entomology and Malaria Control (CNM). National treatment guidelines for malaria in Cambodia. Phnom Penh: Ministry of Health; 2022."},{"key":"5691_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1473-3099(23)00430-9","volume":"24","author":"RJ Commons","year":"2024","unstructured":"Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:172\u201383.","journal-title":"Lancet Infect Dis"},{"key":"5691_CR25","unstructured":"WHO. Guidelines for malaria, 30 November 2024 [Internet]. Geneva: World Health Organization; 2024 [cited 2024 Dec 12]. Available from: https:\/\/iris.who.int\/handle\/10665\/379635"},{"key":"5691_CR26","unstructured":"GSK. Brazil and Thailand become first malaria-endemic countries to launch new single-dose radical cure medicine to prevent the relapse of Plasmodium vivax malaria [Internet]. GSK. 2024 [cited 2024 Dec 11]. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/brazil-and-thailand-become-first-malaria-endemic-countries-to-launch-new-single-dose-radical-cure-medicine\/#:~:text=Approvals%20for%20tafenoquine%20have%20been,vivax%20is%20endemic"},{"key":"5691_CR27","unstructured":"Medicines for Malaria Venture. First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines [Internet]. Geneva, Medicines for Malaria Venture. 2024. Available from: https:\/\/www.mmv.org\/newsroom\/news-resources-search\/first-single-dose-medicine-p-vivax-malaria-prequalified-who-and"},{"key":"5691_CR28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","volume":"383","author":"A Llanos-Cuentas","year":"2014","unstructured":"Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049\u201358.","journal-title":"Lancet"},{"key":"5691_CR29","unstructured":"GSK. KRINTAFEL (tafenoquine) Tablets Perscribing Information [Internet]. GSK; 2023 [cited 2025 Mar 9]. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Krintafel\/pdf\/KRINTAFEL-PI-PIL.PDF"},{"key":"5691_CR30","unstructured":"U.S. Center for Disease Control. Change in Krintafel (tafenoquine) Label [Internet]. 2020 Feb [cited 2023 Jan 17]. Available from: https:\/\/www.cdc.gov\/malaria\/new_info\/2020\/tafenoquine_2020.html"},{"key":"5691_CR31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(23)00213-X","volume":"23","author":"I Sutanto","year":"2023","unstructured":"Sutanto I, Soebandrio A, Ekawati LL, Chand K, Noviyanti R, Satyagraha AW, et al. Tafenoquine co-administered with dihydroartemisinin\u2013piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. Lancet Infect Dis. 2023;23:1153\u201363.","journal-title":"Lancet Infect Dis"},{"key":"5691_CR32","doi-asserted-by":"publisher","unstructured":"Degaga TS, Pasaribu AP, Tripura R, Ghanchi N, Rajasekhar M, Adhikari B, et al. Effectiveness and safety of high dose primaquine and tafenoquine in Plasmodium vivax patients (EFFORT) - a multi-centre, open label, superiority randomised controlled trial. Preprint [Internet]. Available from: https:\/\/doi.org\/10.2139\/ssrn.5409116","DOI":"10.2139\/ssrn.5409116"},{"key":"5691_CR33","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S1473-3099(25)00033-7","volume":"25","author":"V Eng","year":"2025","unstructured":"Eng V, Lek D, Sin S, Feufack-Donfack LB, Orban A, Salvador J, et al. 14 days of high-dose versus low-dose primaquine treatment in patients with Plasmodium vivax infection in Cambodia: a randomised, single-centre, open-label efficacy study. Lancet Infect Dis. 2025;25:884\u201395.","journal-title":"Lancet Infect Dis"},{"key":"5691_CR34","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1473-3099(23)00265-7","volume":"23","author":"K Thriemer","year":"2023","unstructured":"Thriemer K, Commons RJ. Tafenoquine and artemisinin-based combination therapy for vivax malaria: end of the road or just the beginning? Lancet Infect Dis. 2023;23:1100\u20132.","journal-title":"Lancet Infect Dis"},{"key":"5691_CR35","unstructured":"Roth A. A high throughput platform for relapsing malaria drug discovery. ASTMH Annual Meeting; 2022; Seattle, Washington."},{"key":"5691_CR36","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50474","volume":"212","author":"RJ Commons","year":"2020","unstructured":"Commons RJ, McCarthy JS, Price RN. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6 PD deficiency. Med J Aust. 2020;212:152.","journal-title":"Med J Aust"},{"key":"5691_CR37","unstructured":"WHO. Guidelines for malaria, 13 August 2025 [Internet]. Geneva, World Health Organization; 2025 [cited 2025 Sept 23]. Available from: https:\/\/iris.who.int\/handle\/10665\/382254"},{"key":"5691_CR38","doi-asserted-by":"crossref","unstructured":"Cassidy-Seyoum SA, Adhikari B, Chheng K, Chanpheakdey P, Meershoek A, Hsiang M, et al. Acceptability and feasibility of glucose-6-phosphate dehydrogenase (G6PD) testing using SD biosensor by village malaria workers in Cambodia: a qualitative study [Internet]. 2024 [cited 2024 Nov 7]. Available from: https:\/\/www.ssrn.com\/abstract=4964609","DOI":"10.2139\/ssrn.4964609"},{"key":"5691_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12936-022-04300-9","volume":"21","author":"B Adhikari","year":"2022","unstructured":"Adhikari B, Tripura R, Dysoley L, Callery JJ, Peto TJ, Heng C, et al. Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia. Malar J. 2022;21:282.","journal-title":"Malar J"},{"key":"5691_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/pathogens12030400","volume":"12","author":"B Adhikari","year":"2023","unstructured":"Adhikari B, Tripura R, Dysoley L, Peto TJ, Callery JJ, Heng C, et al. Glucose-6-phosphate dehydrogenase (G6PD) measurement using biosensors by community-based village malaria workers and hospital laboratory staff in Cambodia: a quantitative study. Pathogens. 2023;12:400.","journal-title":"Pathogens"},{"key":"5691_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12936-025-05425-3","volume":"24","author":"SA Cassidy-Seyoum","year":"2025","unstructured":"Cassidy-Seyoum SA, Mwaura M, Chheng K, Kejela M, Korra KG, Wodaj T, et al. Co-design of a routine clinical review to improve the safety of high dose radical cure treatment for Plasmodium vivax malaria: findings from Cambodia and Ethiopia. Malar J. 2025;24:171.","journal-title":"Malar J"},{"key":"5691_CR42","unstructured":"Devine A. The cost-effectiveness of high dose short course primaquine and tafenoquine. Symposium Presentation presented at: ASTMH Annual Meeting; 2024 Nov 17."},{"key":"5691_CR43","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12936-025-05525-0","volume":"24","author":"SA Cassidy-Seyoum","year":"2025","unstructured":"Cassidy-Seyoum SA, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, von Seidlein L, et al. Perceptions of shorter radical cure Plasmodium vivax treatment regimens and their implementation: a qualitative study among stakeholders in Cambodia. Malar J. 2025;24:304.","journal-title":"Malar J"},{"key":"5691_CR44","doi-asserted-by":"crossref","unstructured":"Cassidy-Seyoum SA, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, von Seidlein L, et al. Community patient follow-up as a part of P. vivax case management in Cambodia: a mixed methods study [Internet]. 2025 [cited 2025 May 16]. Available from: https:\/\/www.researchsquare.com\/article\/rs-6423610\/v1","DOI":"10.21203\/rs.3.rs-6423610\/v1"},{"key":"5691_CR45","unstructured":"WHO. World Malaria Report 2024: addressing inequity in the global malaria response [Internet]. Geneva: World Health Organization; 2024 [cited 2025 Jan 24]. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024"},{"key":"5691_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003086","volume":"4","author":"CA Lynch","year":"2024","unstructured":"Lynch CA, Lhazeen K, Shrestha M, Ruwanpura V, Valecha N, Thriemer K. Eliminating malaria in our time. PLoS Glob Public Health. 2024;4:e0003086.","journal-title":"PLoS Glob Public Health"},{"key":"5691_CR47","doi-asserted-by":"crossref","unstructured":"Ruwanpura VSH, Nowak S, Gerth\u2010Guyette E, Theodora M, Dysoley L, Haile M, et al. Further evidence needed to change policy for the safe and effective radical cure of vivax malaria: Insights from the 2019 annual APMEN Vivax Working Group meeting. Asia Pac Policy Stud. 2021 Jan 12;app5.314.","DOI":"10.1002\/app5.314"},{"key":"5691_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002990","volume":"4","author":"VSH Ruwanpura","year":"2024","unstructured":"Ruwanpura VSH, Grietens KP, Price RN, Thriemer K. Evidence uptake is only part of the process: stakeholders\u2019 insights on WHO treatment guideline recommendation processes for radical cure of P. vivax malaria. PLoS Glob Public Health. 2024;4:e0002990.","journal-title":"PLoS Glob Public Health"},{"key":"5691_CR49","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1016\/S2214-109X(23)00542-9","volume":"12","author":"M Brito","year":"2024","unstructured":"Brito M, Rufatto R, Murta F, Sampaio V, Balieiro P, Ba\u00eda-Silva D, et al. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis. Lancet Glob Health. 2024;12:e467\u201377.","journal-title":"Lancet Glob Health"},{"key":"5691_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(24)00074-4","volume":"24","author":"M Brito","year":"2024","unstructured":"Brito M, Rufatto R, Brito-Sousa JD, Murta F, Sampaio V, Balieiro P, et al. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study. Lancet Infect Dis. 2024;24:629\u201338.","journal-title":"Lancet Infect Dis"},{"key":"5691_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41182-024-00607-2","volume":"52","author":"D Lek","year":"2024","unstructured":"Lek D, Sokomar N, Samphornarann T, Rideout J, Hassan SED, Bunkea T, et al. Impact of targeted drug administration and intermittent preventive treatment for forest goers using artesunate\u2013pyronaridine to control malaria outbreaks in Cambodia. Trop Med Health. 2024;52:42.","journal-title":"Trop Med Health"},{"key":"5691_CR52","unstructured":"Chindavongsa K. Effectiveness of tafenoquine and primaquine: programmatic reflections: integrating radical cure innovations in Lao PDR [Internet]. APMEN Tech Talks; 2025 May 26. Available from: https:\/\/www.youtube.com\/watch?v=bCnXIEUixNE"},{"key":"5691_CR53","unstructured":"APMEN VxWG. Strengthening vivax radical cure strategies in the GMS: a regional dialogue [Internet]. Asia Pacific Malaria Elimination Network. 2025. Available from: https:\/\/www.apmen.org\/blog\/strengthening-vivax-radical-cure-strategies-gms-regional-dialogue"},{"key":"5691_CR54","unstructured":"PATH. SD BIOSENSOR receives WHO prequalification of the STANDARD G6PD Test [Internet]. PATH. 2025 [cited 2025 Feb 7]. Available from: https:\/\/www.path.org\/our-impact\/media-center\/sd-biosensor-receives-who-prequalification-of-the-standard-g6pd-test\/"},{"issue":"6 Suppl","key":"5691_CR55","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4269\/ajtmh.16-0182","volume":"95","author":"MT White","year":"2016","unstructured":"White MT, Yeung S, Patouillard E, Cibulskis R. Costs and cost-effectiveness of Plasmodium vivax control. Am J Trop Med Hyg. 2016;95(6 Suppl):52\u201361.","journal-title":"Am J Trop Med Hyg"},{"key":"5691_CR56","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jval.2021.01.013","volume":"24","author":"L Conteh","year":"2021","unstructured":"Conteh L, Shuford K, Agboraw E, Kont M, Kolaczinski J, Patouillard E. Costs and cost-effectiveness of malaria control interventions: a systematic literature review. Value Health. 2021;24:1213\u201322.","journal-title":"Value Health"},{"key":"5691_CR57","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789\u2013858.","journal-title":"Lancet"},{"key":"5691_CR58","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/14737167.2018.1494574","volume":"18","author":"J Pattanaphesaj","year":"2018","unstructured":"Pattanaphesaj J, Thavorncharoensap M, Ramos-Go\u00f1i JM, Tongsiri S, Ingsrisawang L, Teerawattananon Y. The EQ-5D-5L vluation study in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2018;18:551\u20138.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05691-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05691-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05691-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T20:02:46Z","timestamp":1767470566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-025-05691-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5691"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05691-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LD is a member of the Cambodian national treatment guideline committees. AD and RNP participated in the World Health Organization Guideline Development Group on near-patient G6PD tests to support safe and effective\n                      P. vivax\n                      anti-relapse treatment. PR is a staff member of WHO. The author alone is responsible for the views expressed in this publication, which do not necessarily represent the decisions, policies, or views of WHO.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}